The last 10 global press releases

To find more press releases: 

2022
2021
2020
2019
2018
2017
2016
September 29, 2022
Press releases
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
September 28, 2022
Press releases
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
September 16, 2022
Press releases
Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease
September 16, 2022
Press releases
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
September 16, 2022
Press releases
Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet
September 8, 2022
Press releases
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
September 6, 2022
Press releases
Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases
September 5, 2022
Press releases
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
September 5, 2022
Press releases
Press Release: Evolution of the Board of Directors
August 31, 2022
Press releases
Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

The last 5 COVID-19 press releases

Local press releases

September 3, 2020 - US
Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO

September 9, 2020 - US
Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020